Clinical trial
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma
NCT00012064 · Lisata Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT00012064 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma |
| Official title | Vaccine Biotherapy of Cancer: Tumor Cells and Dendritic Cells as Active Specific Immunotherapy of Patients With Metastatic Melanoma |
| Lead sponsor | Lisata Therapeutics, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | therapeutic autologous dendritic cells |
| Enrollment | 56 |
| Start date | Jul 1, 2000 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 29, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: